^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 negative + AR positive + ER positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; ESR1, Era, ESR, NR3A1, ER, ER beta; AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
    Entrez ID:
    2064; 2099; 367
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    3d
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (clinicaltrials.gov)
    P4, N=75, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Avastin (bevacizumab)
    4d
    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant
    18d
    PANSY: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (clinicaltrials.gov)
    P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
    1m
    Encapsulated papillary carcinoma with invasion in the breast: A case report with imaging findings. (PubMed, Radiol Case Rep)
    Postoperative recovery was uneventful, and she remained recurrence-free on tamoxifen therapy for 2 years. This case highlights key imaging features suggestive of invasion in EPC, which may facilitate preoperative assessment and management.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen
    1m
    Utility of Quantitative Parameters From Triple-Phase Contrast Enhanced Dual-Energy CT for Predicting Immunohistochemical Biomarkers in Invasive Breast Cancer. (PubMed, J Med Imaging Radiat Oncol)
    Triple-phase DECT-derived parameter AEF was identified as a useful negativity predictor for ER and PR levels, while ERVE was demonstrated as a positivity predictor of HER2 status in invasive breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    1m
    Exploratory Clinical Study of Camrelizumab Combined with Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer (ChiCTR2500109774)
    P2, N=12, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKa (camrelizumab) • Halaven (eribulin mesylate)
    2ms
    Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial. (PubMed, Int J Cancer)
    We conducted a secondary analysis of the Stockholm tamoxifen (STO-5) randomized controlled trial (1990-1997) with 20-year complete follow-up, including 924 premenopausal women with operable breast cancer in Stockholm, Sweden...Patients with high PR heterogeneity significantly benefited from endocrine therapy (HR = 0.41; 95% CI, 0.24-0.71). These findings suggest that premenopausal patients with high PR heterogeneity have increased long-term risk but significantly benefit from endocrine therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen
    2ms
    Spontaneous Regression (SR) of Male Breast Cancer (MBC): A Rare Case Highlighting Diagnostic Pitfalls and Management Caution. (PubMed, Case Rep Surg)
    This case not only emphasizes the rarity of MBC but also draws attention to the exceptional phenomenon of SR in invasive carcinoma. Recognition of such rare events underscores the importance of cautious decision-making, multidisciplinary management, and further research into the biological and immunological mechanisms underlying tumor regression.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
    2ms
    Metachronous breast and rectal cancer: A clinical case report and review. (PubMed, Int J Surg Case Rep)
    The diagnosis and treatment of metachronous malignancies, particularly involving the breast and rectum, are inherently complex. Optimal patient outcomes necessitate a comprehensive, coordinated, and individualized approach, emphasizing the importance of long-term surveillance and adaptable management strategies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
    3ms
    Characteristics and prognosis of Her2-negative breast cancer expressing unbalanced hormone receptor. (PubMed, BMC Womens Health)
    Endocrine resistance may be the cause of poor survival of NP and PN, and should be combined with other treatments such as actual intensive chemotherapy. Although the clinical number of NP breast cancer is small, it still needs attention.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 expression • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    3ms
    DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Criterium, Inc. | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Signatera™ • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Ibrance (palbociclib) • fulvestrant
    3ms
    Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. (clinicaltrials.gov)
    P2, N=43, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib)